Organic EL Device with Different Host Materials

The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.

USPTO Grants Patent for Nanoporous Material for Ion Channels

The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.

USPTO Patent Grant for API Crystalline Form Preparation

The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.

USPTO Patent Grant US12583859B2 for PRMT5 Inhibitors

The USPTO has granted patent US12583859B2 to the California Institute of Technology for PRMT5 inhibitors. The patent covers compounds and methods useful in treating cancers and other diseases.

Genentech, Inc. Granted Patent for TDO2 Inhibitors

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

USPTO Patent US12583857B2 for Anti-liferative Agents

The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.

Amgen KRAS G12C Inhibitors Patent Granted

The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.

USPTO Patent Grant for BCL-2 Inhibitors

The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.

USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy

The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.

USPTO Patent Grant: Pyrazine Derivatives for Pest Control

The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.